# Assured Med Supply (AMS.AI) AI Co-Pilot that could transform the $1.3 Trillion Medical Distribution Market - Canonical URL: https://wefunder.com/assured.med.supply - Entity ID: wefunder:company:131037 - Last updated: 2026-06-25T05:02:19Z - Generated at: 2026-06-25T18:31:29Z ## Quick facts - Transforming the Future of the $1.3 Trillion Medical Distribution Industry with AI - Self-made success story: Prior to pivoting to AI, our medical supply business achieved $5M+ revenue - Our medical supply business had year-on-year growth of over 100% with no outside debt or investment - Al-powered healthcare solutions are projected to save Americans $150B annually by 2026 - Secured key distribution partnerships, including SIEMENS ($100B+ market cap) - Our primary customers include the #2-ranked hospital in America and other top-100 U.S. hospitals - Clients include the world's 2nd largest healthcare company, Thermo Fisher + 5 Fortune-500 companies - Leadership team featured on Forbes, CNBC, TED Talk, TechCrunch, and other major media ## Active fundraises - wefunder:fundraise:80496: 4(a)(6) successful (USD) - wefunder:fundraise:80497: 4(a)(6) successful (USD) ## Story During our first three years working in the traditional medical supply industry, Assured Med Supply (AMS) achieved an annual growth rate of over 100% year-on-year without any outside financing or debt. We secured partnerships with top hospitals (ranked in the U.S. top 100) and multiple large Fortune 500 clients.As seasoned medical industry insiders with a rare blend of tech expertise, we uncovered a major gap in the $1.3 trillion medical distribution market. Recognizing the immense potential to address the #2 biggest expense for hospitals, we recently made a decisive pivot into AI. This strategic leap empowers us to eliminate critical inefficiencies in the medical supply chain, leveraging our proven healthcare success and extensive client base. As a pure-play AI healthcare company with an elite AI team, we are ready to lead the medical supply industry into a new era of AI-driven innovation.Sources: Harvard Business Review, Navigant, Medical Economics, Chief HealthcareWhile growing our existing medical supply business, we realized that our past successes and AI experience uniquely position us to address many of these medical supply challenges with AI. Since 2023, we have been operating as a pure AI company, fully focused on developing technology such as:AI Conversational Chat Interface – hospital and clinic buyers can communicate purchasing needs in real-time and receive immediate feedback for decision-making based on an AI-powered natural human language chat interfaceDynamic AI-Powered Marketplace – buyers can view available inventory across an aggregated set of pre-qualified vendors, receive automated price comparisons, and even benefit from dynamic group buying algorithms to further reduce costsVisualization & Analysis AI Dashboards – buyers can review key information such as product substitution options and predictive analysis on delivery schedules and inventory pipelines to make better decisions on purchasing and inventory planningEnterprise Integration – our platform integrates easily with dominant legacy ERP systems like SAP and major purchasing gateway systems like GHX to ensure ease of adoption for our healthcare customersFuture projections are not guaranteed.Source: PWCDistinct from many other startups, we have shown that we can successfully grow our Company. We also have several years of experience in the medical supply business space, and the added advantage of already having some of the world’s leading hospitals and medical companies as our customers. We plan to leverage our prior success and unique experience in medical supplies, AI chatbots, messaging, logistics, and marketplaces for a best-in-class solution.The Revenue ModelAI–SaaS Subscriptions – hospital buyers pay an annual subscription fee for the intelligent AI marketplace, AI purchasing assistant, and smart analyticsAI Marketplace Platform Fees – medical vendors pay a percentage of the value of any sales they conduct via the marketplace platformWe aim to achieve over $20M of total revenue in the first two full years of our new AI platform operation, and project that we will scale to over $100M in 2028Current Round Offering: $1,234,925 ## FAQ 1. **Do you have any patents? Why did your revenue go down in 2023 compared with 2022?** - Grigore, thank you very much for your 2 great questions and interest in AMS.AI / Assured Med Supply. Our proprietary technology will focus on highly accurate algorithms for AI-powered medical product selection and AI vendor matching, supported by proprietary data, all of which we will protect as trade secrets. Like many generative AI startups, we are prioritizing a trade secrets strategy over patents at this stage to focus our resources on developing platforms that hospitals—which require the... 2. **Hi, are you all planning to maintain the current S-corp status of the company for tax purposes, so long as there are ultimately fewer than 100 shareholders?** - Lucas, thank you for asking and for your interest in AMS.AI / Assured Med Supply. Based on the legal and accounting advice we've received, we plan to switch to filing taxes as a C Corp close to or upon the finalization of the raise. 3. **Where does your co-pilot sit? You call it an AI SaaS, so is it a duplicative system that administrators need to access, or does it fully integrate into common purchasing platform? A slightly different question, where exactly do you play in the buying value chain? Given the per...** - Hi Lance, Thank you for your thoughtful and insightful question. We’d love to have someone with your healthcare industry experience as part of our AMS.AI / Assured Med Supply. investor base, providing valuable insights. To address your points, we initially plan to launch as a standalone AI platform designed to assist key hospital decision-makers in making more informed and efficient purchasing decisions. Think of it like how AI tools are revolutionizing financial trading for banks and hedge f... 4. **What is the price per share/unit? According to your custom contract (subscription agreement), the price is $10.51 per unit but my Wefunder receipt is showing , $1 per unit.** - Thank you for your excellent question, Efosa, and for supporting us! I can confirm that the correct price per unit is indeed $10.51, as you read and is outlined in the subscription agreement. I’ve also double-checked with WeFunder regarding your specific issue with receipt, and they’re making/made all necessary internal adjustments on their end. Rest assured, everything will reflect accurately moving forward. 5. **Regarding the use of funds, I note intended funds to be repaid to management. At this early stage of the game I question why I should enter as others exit at $10.51 that have considerably more knowledge than supplied, at a buck might be worth a shot. Anything else to consider ?** - Thank you for your question, Roger, and for taking the investment process seriously—your diligence embodies the thoughtful approach we value in investors. No one from management is selling shares into this round or exiting their positions to profit personally on the current raise. Every dollar raised is being reinvested to further the company, accelerate product development, and drive valuation growth for all shareholders. At this stage, selling shares for the specific purpose of taking money... ## Team - Roy Malkin (Co-Founder, CEO) - Gary Lipsky (Co-Founder, COO) - Don Oparah (Co-Founder, Advisor) - Vyacheslav Kungurtsev (Chief AI Scientist) - Alejandro Narancio (CTO) ## Q&A - Q: Are we going to get any updates on what is going on with AMS? Maybe an AMA? I haven't heard anything in over as month - Q: Do you have any patents? Why did your revenue go down in 2023 compared with 2022? - A: Grigore, thank you very much for your 2 great questions and interest in AMS.AI / Assured Med Supply. Our proprietary technology will focus on highly accurate algorithms for AI-powered medical product selection and AI vendor matching, supported by proprietary data, all of which we will protect as trade secrets. Like many generative AI startups, we are prioritizing a trade secrets strategy over patents at this stage to focus our resources on developing platforms that hospitals—which require the highest accuracy in their AI solutions—will find indispensable. This approach aligns with the broader trend for generative AI startups, where the need for speed, flexibility, and confidentiality in a rapidly evolving field often makes trade secrets more practical than patents. That being said, we will be exploring filing patents shortly after our raise, related to how our AI (1) identifies substitutes, (2) facilitates unique vendor matching, and (3) generates unique hospital reporting through a distinctive UI. In 2023, we fully transitioned to a pure AI company. While this may sacrifice short-term revenue, it strategically positions us to leverage our strong healthcare customer base and tap into the massive $1.3 trillion medical distribution market in a new and potentially far more profitable way. We believe the upside of being a pure AI company is significantly greater than in our traditional business, as demonstrated to us by the amazing success of other generative AI companies like OpenAI and Anthropic. - Q: Maybe I missed it, but what are the exit plans? Thanks! - A: Great question. Here are our 2 major exit plans: 1) Acquisition by a major healthcare, AI, or logistics company – Given our partnerships and the scale of the problem in a $1.3T market we’re solving, a strategic acquisition is a strong possibility. 2) IPO – My last co-founded company is considering an IPO next year, and AMS AI has the potential to follow a similar trajectory, at AMS AI, we will be targeting a public offering on Nasdaq once we reach significant key revenue and market adoption milestones - Q: Where does your co-pilot sit? You call it an AI SaaS, so is it a duplicative system that administrators need to access, or does it fully integrate into common purchasing platform? A slightly different question, where exactly do you play in the buying value chain? Given the percentage of the U.S. healthcare system that is locked into exclusive GPO buying contracts, are you collaborating with the big GPOs? Your competitive chart would seem to imply not (eg Vizient). Is your ultimate strategy to create your own GPO network? For background, I've spent the last 15 years in med tech. Of the $1.3T in medical purchases, 98% flow through GPOs (with 76% of them being completely exclusive or categorically exclusive). If I strip away the AI buzz factor, I'm trying to ascertain where the opportunity is. Your addressable market size would seem to be the 2% not tied to GPOs. Am I missing something? - A: Hi Lance, Thank you for your thoughtful and insightful question. We’d love to have someone with your healthcare industry experience as part of our AMS.AI / Assured Med Supply. investor base, providing valuable insights. To address your points, we initially plan to launch as a standalone AI platform designed to assist key hospital decision-makers in making more informed and efficient purchasing decisions. Think of it like how AI tools are revolutionizing financial trading for banks and hedge funds—processing vast amounts of data in real-time to make smarter predictions in micro-seconds and reduce risks. Our system will support procurement and supply chain teams similarly, optimizing workflows and reducing inefficiencies. As we refine our model and gain traction, we plan to integrate with existing ordering systems, or they may eventually become compatible with ours as we scale to become the industry standard. We’re following Peter Thiel’s philosophy of building a "beachhead" by starting with a targeted, solvable problem—such as medical supply shortages—and expanding from there. Our slide, "Our Vision for Growth," clearly outlines how we will strategically evolve in parallel to how other big companies started. By focusing on this specific need first, we’ll gain traction and grow from that initial foothold to dominate broader segments of the $1.3T medical distribution market. Much like entrepreneurs such as Elon Musk & Jeff Bezos, we are applying first principles thinking to disrupt this industry. We started by dissecting the core problems in healthcare procurement—hospitals are highly inefficient when managing shortages, finding alternative vendors, and frequently overpaying for essential supplies. On top of that, these supplies often arrive late, especially during disruptions like those experienced during the COVID-19 pandemic. Many hospitals experienced significant shortfalls from their GPO contract suppliers during that time and are now focused on building more resiliency into their supply chains. When there is another "black swan" event (war, pandemic, instability in a key country that supplies medical equipment. major product recall.), AI platform like ours can quickly shift purchasing/new vendors rapidly, and Hospitals cannot afford to wait on how such events play out as lives are at stake. Even within the GPO system, inefficiencies persist, and we believe AI can drive significant improvements in this area. Our initial focus will be on addressing the 20% of medical supplies currently in shortage and areas not fully covered by GPOs. This market alone likely represents hundreds of billions of dollars, and we see immense potential here. We remain open to working with GPOs in the future. The bottom line is that we’re creating real value for hospitals by offering a quick, scalable solution to reduce shortages and access non-GPO products. As we scale, hospitals will have an efficient alternative for managing procurement, and larger institutions may even explore factory-direct options or other cost-saving measures. This market is enormous, and AI is one of the keys to unlocking its potential. Additionally, if we feel it would maximize value for the company and investors, the option of creating our own specialized AI-powered GPO based on the significant data and insights we will generate remains a potential strategic angle for our venture over the longer term. We’d be thrilled to have you join us as an investor on this exciting journey. - Q: Do you already have an app development team in place? - Q: Are you still accepting investments now that you are oversubscribed or are you taking as much money as possible until closing date? - Q: Where is the AI product now? Is there an MVP, a working prototype, or customer pilots? What are short-term revenue milestones? When do you expect first paying AI clients? How will funds from this round be used? (Breakdown of development, hiring, marketing) What does success look like in 6–12 months? (Customers, revenue, tech readiness) What is your competitive moat? (What keeps others from copying this?) - Q: Thanks for taking my call yesterday. - A: 👍 - Q: Will you and your team be giving updates (monthly, weekly) on the progress you are making in trying to build this project? I am extremely bullish on this concept for so many reasons and am ready to invest more money in the coming weeks. If people haven't noticed - there has been a dramatic change (in the last several weeks) in the way our government is focusing on waste, fraud, and inefficiency on how they spend the taxpayers money. The healthcare industry is a prime example. I also believe this project is recession-proof. The timing could not be better for this project. Can't wait to hear your updates on how the project is progressing. Thanks - A: Great question, as always, Michael. We’re planning to host a live Q&A between mid-March and mid-April, which might be the best forum to discuss all our progress in more detail. We will make an announcement ahead of the date. That being said, the recent DeepSeek copying of OpenAI is making the entire U.S. AI industry super cautious about what they release publicly and how soon before any new feature releases. One advantage we have is that U.S. hospitals are highly unlikely to work with non-U.S. AI companies due to the sensitivity of their data. In contrast, OpenAI operates a consumer model where end users are generally less concerned about data privacy from a foreign competitor. Regarding your DOGE comment, we’ve positioned ourselves as DOGE for hospitals before DOGE was even a concept! It is recession-proof, in the sense that Hospitals look to cut costs even more during a recession, and they spend on supplies no matter what happens in economy. - Q: Has the transformer been trained with your own funds on proprietary data or you a second layer APP？ AI is still at the beginning and the mainstream narrative mentions that SAAS model is not future proof: what your hedges? - A: Our transformer is trained on proprietary data, ensuring a unique and competitive edge. While we leverage foundational models where it makes sense (for speed, cost, and efficiency to go to market), we’re not just a second-layer app—we enhance AI with exclusive datasets and domain-specific optimizations. Regarding your SaaS question, we "hedge" these risks not only by embedding AI directly into critical healthcare workflows, but also by adopting a hybrid revenue model beyond subscriptions, and forming deep industry partnerships but also by creating lock-in through a marketplace model with strong network effects. Our platform is an increasingly integrated AI ecosystem for the healthcare supply chain that becomes better and more indispensable over time the more its used. Just like launching a 30% better software version of eBay or Facebook marketplace wouldn’t instantly shift its user base to a new platform, our marketplace ensures that once vendors and buyers are engaged, the increasing value of the network makes it difficult to replicate or disrupt. As a team, we’ve built multiple successful marketplaces, facilitating billions of USD in transactions, and we are confident we can replicate our past success with a platform with long-staying power and scalability. The marketplace will be integrated in phases, ensuring a seamless transition and long-term adoption. Mirko, given your publicly stated commitment to making the world a better place, we would love to have you as a significant impact investor in AMS AI. Through our work in the medical industry and our goal of becoming a healthcare AI unicorn, we are actively helping rural hospitals cut costs and stay in business despite financial challenges—with 30% at risk of closure, leaving rural communities without timely access to critical care, which can have catastrophic consequences. Additionally, we are working to prevent life-saving procedure delays, like surgeries, caused by persistent medical supply shortages. - Q: Can we still invest more money at the pre-raise valuation of 9M at a later date? Or do the terms change after the rolling close date on Feb 11th? Thanks - A: Good question, Michael. The close date is set for April 29, 2025; as far as I know, the valuation remains the same. Investing early rather than waiting on the sidelines until the last minute is in everyone's best interest. Those who move now help fuel the momentum of other investors coming in—and stand to gain the most from it as we can bring more features to market earlier and push as hard as we can to get maximum adoption of our product with hospitals. AI is capital intensive, but as you saw with Palantir's earnings announcement today and OpenAI's $300B+ valuation last week, it's worth it, and we only began to scratch the surface of the ROI investors can expect from AI companies. - Q: Hello Roy, do you have any updates? - Q: i invested on Feb 9, 2025 $1,000 but i do not see the number of shares ? Regards Richard Clement - Q: hello ! hope all is well what are your monthly revenues/expenses this first quarter ? Dr Richard Clement - Q: Hi Roy, when live Q&A will occur ?